Previous Study: CIRG/TORI 010
Next Study: TRIO 013

Studies & Results

TORI L-03

Phase II erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer.

Presentations

AACR Annual Meeting , 2013

Garon EB, Siegfried JM, Dubinett SM, et al

Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).

Publications

Garon EB, Siegfried JM, Dubinett SM, et al: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). AACR 104th Annual Meeting, 2013

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org